Neurobiological Technologies, Inc. (NTII)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Neurobiological Technologies, Inc. (NTII) trades at $0.00 with AI Score 68/100 (Grade B+). Neurobiological Technologies, Inc. (NTII) operates under a plan of liquidation and dissolution, approved by stockholders in October 2009. Market cap: $2,702, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for NTII: NTII does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NTII against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NTII: 4/6 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Neurobiological Technologies, Inc. (NTII) Healthcare & Pipeline Overview
Neurobiological Technologies, Inc. is a former biotechnology firm, established in 1987, currently undergoing a formal liquidation and dissolution process initiated in 2009. Its operations are focused on winding down its corporate affairs and distributing remaining assets, rather than active drug development or commercial activities in the healthcare sector.
What Is the Investment Thesis for NTII?
Neurobiological Technologies, Inc. (NTII) presents a unique investment profile, primarily defined by its ongoing plan of liquidation and dissolution, approved in October 2009. The core 'value driver' for current or potential investors is the potential for final distributions of remaining assets to shareholders, rather than operational performance or future growth. The company's market capitalization is reported as $0.00B, reflecting its non-operational status. Key considerations revolve around the efficiency and timeline of the liquidation process, including the resolution of any outstanding liabilities and the monetization of residual assets. With a reported profit margin of 11.9% and a gross margin of 99.5%, these metrics likely reflect past financial activities or specific asset sales rather than ongoing business profitability. The negative beta of -410.84 suggests an inverse and highly volatile relationship with the broader market, which is atypical and may be a statistical anomaly given its non-operational status. Risks include the potential for unforeseen liabilities, the costs associated with the liquidation process, and the uncertainty regarding the final net asset value available for distribution. There are no traditional growth catalysts or operational milestones to monitor, as the company's objective is to cease operations.
Based on FMP financials and quantitative analysis
NTII Key Highlights
- Market Capitalization of 3K reflects the company's non-operational status and ongoing liquidation process.
- Profit Margin stands at 11.9%, likely indicative of specific asset sales or financial events rather than recurring operational profitability.
- Gross Margin of 99.5% suggests minimal cost of goods sold, consistent with a company no longer engaged in active product development or manufacturing.
- Beta of -410.84 indicates an unusual and highly inverse correlation with market movements, which may be a statistical artifact given the company's liquidation status.
- The company has 4 employees, reflecting a minimal operational footprint focused solely on managing the dissolution process.
Who Are NTII's Competitors?
NTII is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
| ZYME Zymeworks Inc. | $25.42 | -3.39% | $1.87B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NTII's Key Strengths?
- Clear mandate for liquidation, providing a defined endpoint for corporate activities.
- Minimal operational overhead with only 4 employees, reducing ongoing costs during dissolution.
- Established legal framework for asset distribution to shareholders.
What Are NTII's Weaknesses?
- No ongoing revenue-generating operations or active business model.
- Limited transparency and disclosure status (Unknown) for OTC trading.
- Potential for prolonged liquidation process, delaying final distributions.
- Historical drug development pipeline is no longer active or a source of value.
What Could Drive NTII Stock Higher?
- Resolution of outstanding corporate liabilities and claims, which is a necessary step before final asset distribution.
- Finalization of asset divestments, leading to a clearer picture of the net proceeds available for shareholders.
- Announcement of a definitive timeline or estimated value for the final cash distribution to shareholders.
- Administrative closure of corporate entities and legal obligations, paving the way for complete dissolution.
What Are the Key Risks for NTII?
- Financial-distress signal — its Altman Z-Score of -2.09 sits in the distress zone (elevated bankruptcy risk).
- Prolonged liquidation process, potentially delaying the final distribution of assets to shareholders for an extended period.
- Unforeseen liabilities or legal challenges emerging during the dissolution, which could reduce the net asset value available for distribution.
- Erosion of remaining asset value due to administrative costs, legal fees, and other expenses incurred during the liquidation.
- Difficulty in monetizing remaining assets at favorable prices, especially illiquid or specialized intellectual property.
- Lack of transparency due to 'Unknown' disclosure status, making it challenging for investors to monitor the liquidation progress and financial health.
What Are the Growth Opportunities for NTII?
- Absence of New Product Development Due to Liquidation: Neurobiological Technologies, Inc. ceased all drug development activities and research programs following the approval of its liquidation plan in October 2009. Consequently, there are no growth opportunities stemming from the development or commercialization of new investigational drugs, therapeutic compounds, or medical technologies. The company's historical focus on human diseases is no longer an active area of investment or operational pursuit, meaning traditional biotechnology growth drivers, such as pipeline advancements or regulatory approvals, are entirely absent from its current corporate strategy and outlook.
- No Market Expansion Initiatives: As a company undergoing formal dissolution, Neurobiological Technologies, Inc. is not pursuing any market expansion strategies, whether into new therapeutic areas, geographic regions, or patient demographics. The objective is to wind down operations, not to grow or extend its market reach. Therefore, opportunities typically associated with market penetration, diversification, or internationalization, which are common growth avenues for active biotechnology firms, do not apply to NTII in its current state of liquidation and corporate closure.
- Lack of Strategic Partnerships or Acquisitions: Companies in the biotechnology sector often leverage strategic partnerships, collaborations, or acquisitions to expand their research capabilities, access new markets, or accelerate drug development. However, Neurobiological Technologies, Inc.'s current mandate is to liquidate and dissolve. This precludes any initiatives for forming new alliances, engaging in joint ventures, or acquiring other entities. Its focus is entirely inward-looking, concentrating on the administrative and legal requirements of its dissolution rather than external growth-oriented collaborations or M&A activities.
- No Revenue Generation from Core Operations: Neurobiological Technologies, Inc. is no longer actively generating revenue from its historical business model of developing and commercializing investigational drugs. Any financial inflows are likely related to the divestment of remaining assets or the settlement of past financial obligations, rather than ongoing sales of products or services. Therefore, growth opportunities tied to increasing sales volume, expanding service offerings, or improving pricing power, which are fundamental to most operating companies, are not applicable to NTII's current financial profile.
- Focus on Asset Divestment, Not Growth: The primary financial activity for Neurobiological Technologies, Inc. is the orderly divestment of any remaining corporate assets, which could include intellectual property, equipment, or financial holdings. This process is aimed at maximizing the value for distribution to shareholders during liquidation, not at fostering future growth or operational expansion. The timeline for such divestments is dictated by market conditions and the legal requirements of the dissolution, and it represents a terminal event rather than a sustainable growth driver for the company's long-term prospects.
What Opportunities Does NTII Have?
- Efficient monetization of any remaining intellectual property or physical assets.
- Orderly resolution of all outstanding liabilities to maximize shareholder return.
- Final distribution of capital to shareholders, concluding corporate existence.
What Threats Does NTII Face?
- Unforeseen or contingent liabilities emerging during the liquidation process.
- Costs associated with legal and administrative aspects of dissolution eroding asset value.
- Market conditions impacting the value realized from asset divestments.
- Difficulty in attracting liquidity for shares on the OTC market due to liquidation status.
What Are NTII's Competitive Advantages?
- Historically, competitive advantages might have included intellectual property from drug candidates or specialized research expertise in neurobiology.
- Currently, as a company in liquidation, traditional competitive moats are no longer relevant.
- The focus is on administrative efficiency in dissolution, rather than market differentiation or competitive positioning.
What Does NTII Do?
Neurobiological Technologies, Inc. (NTII) was founded in 1987 with a strategic focus on the development of investigational drugs aimed at treating various human diseases within the biotechnology sector. For many years, the company engaged in preclinical and clinical research, striving to bring innovative therapeutic solutions to market. However, a significant shift in its corporate trajectory occurred in October 2009 when its stockholders approved a comprehensive plan of liquidation and dissolution. This pivotal decision marked the cessation of its active drug development programs and a transition to an orderly winding down of all corporate operations. Based in Emeryville, California, the company, which once aimed to contribute to advancements in neurobiological treatments, now functions primarily as an entity managing its dissolution process. With a notably small operational footprint, evidenced by its four employees, NTII's current activities are centered on resolving outstanding liabilities, managing any remaining assets, and ultimately distributing the net proceeds to its shareholders in accordance with the approved liquidation plan. Its historical market position as an early-stage drug developer has been superseded by its current status as a company in the final stages of corporate existence, with no ongoing research, development, or commercial product offerings.
What Products and Services Does NTII Offer?
- Manages the formal liquidation and dissolution process approved by stockholders in October 2009.
- Previously focused on developing investigational drugs for the treatment of human diseases.
- Engaged in research and development activities within the biotechnology sector prior to its liquidation plan.
- Operates with a minimal team of 4 employees, primarily for administrative oversight of the dissolution.
- Based in Emeryville, California, serving as its corporate headquarters for liquidation activities.
- Does not currently engage in active drug development, manufacturing, or commercial sales.
- Aims to resolve outstanding liabilities and distribute remaining assets to shareholders.
How Does NTII Make Money?
- Historically, the business model involved research and development of investigational drugs, with potential revenue from successful commercialization or licensing agreements.
- Currently, the business model is centered on the orderly winding down of corporate operations.
- Financial activities primarily involve the management and divestment of remaining assets.
- Focus is on fulfilling legal and fiduciary duties related to the liquidation plan.
- Any financial returns are derived from the distribution of net assets to shareholders, not from ongoing operational profits.
What Industry Does NTII Operate In?
Neurobiological Technologies, Inc. (NTII) historically operated within the highly specialized and research-intensive biotechnology industry, a sub-sector of healthcare focused on developing drug therapies and diagnostic tools. This industry is characterized by significant R&D investments, lengthy regulatory approval processes, and high-risk, high-reward ventures. Companies typically compete on the efficacy and safety of their investigational drugs, intellectual property, and ability to navigate clinical trials. However, NTII's current status as a company under a plan of liquidation and dissolution, approved in October 2009, means it no longer actively participates in this competitive landscape. Its former positioning involved contributing to the pipeline of investigational drugs for human diseases. Today, it exists outside the active market trends and competitive dynamics of the biotechnology sector, with its focus entirely on administrative closure rather than innovation or market share.
Who Are NTII's Key Customers?
- Historically, potential customers would have been healthcare providers and patients benefiting from its investigational drugs.
- Currently, the company does not have active customers for products or services.
- The primary stakeholders are its shareholders, awaiting the final distributions from the liquidation process.
Company Profile
Neurobiological Technologies, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in EmeryVille, US. The company is led by CEO John B. Stuppin. NTII has traded publicly since 1994.
F-Score 4/9Financial Health
Neurobiological Technologies, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -2.09 places it in the distress zone, a signal of elevated financial risk.
ROE 25%Key Financial Metrics
Return on equity for Neurobiological Technologies, Inc. stands at 24.9%, a gauge of how efficiently it converts shareholder capital into profit. NTII trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. A current ratio of 35.34 indicates the company holds enough short-term assets to cover its near-term obligations.
NTII Valuation & Market Position
With a 3K market cap, Neurobiological Technologies, Inc. sits in the micro-cap segment of the market. Relative to its peer group, NTII's quantitative score of 68/100 is roughly in line with the peer average of 76/100.
NTII Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Clear mandate for liquidation, providing a defined endpoint for corporate activities.
- Minimal operational overhead with only 4 employees, reducing ongoing costs during dissolution.
- Established legal framework for asset distribution to shareholders.
- Ongoing: Resolution of outstanding corporate liabilities and claims, which is a necessary step before final asset distribution.
Bear Case
- No ongoing revenue-generating operations or active business model.
- Limited transparency and disclosure status (Unknown) for OTC trading.
- Potential for prolonged liquidation process, delaying final distributions.
- Historical drug development pipeline is no longer active or a source of value.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
NTII Latest News
No recent news available for NTII.
NTII Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NTII.
Price Targets
Wall Street price target analysis for NTII.
NTII MoonshotScore
What does this score mean?
The MoonshotScore rates NTII's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: John B. Stuppin
Managing Director (implied)
John B. Stuppin serves in a leadership capacity for Neurobiological Technologies, Inc., overseeing the company's operations. Given the company's status as an entity under a plan of liquidation and dissolution since 2009, his role primarily involves managing the winding down of corporate affairs. Specific details regarding his prior career history, educational background, or previous executive roles before joining NTII are not provided in the available source data.
Track Record: Under John B. Stuppin's oversight, Neurobiological Technologies, Inc. has continued its process of liquidation and dissolution, which was approved by stockholders in October 2009. His tenure has been marked by the management of the company's minimal operational footprint, comprising 4 employees, focusing on the administrative and legal aspects required to conclude the company's corporate existence and facilitate the distribution of remaining assets to shareholders.
NTII OTC Market Information
Neurobiological Technologies, Inc. (NTII) trades on the 'OTC Other' tier of the OTC market. This classification typically includes companies that do not meet the disclosure or financial standards required for OTCQX or OTCQB, or those that are distressed, in bankruptcy, or, as in NTII's case, undergoing liquidation. Unlike exchanges like NYSE or NASDAQ, which have stringent listing requirements for financial health, corporate governance, and minimum share prices, 'OTC Other' has minimal to no reporting requirements, making it the lowest tier for public trading. This tier often includes companies that have ceased operations or are in the process of winding down, significantly differentiating them from actively traded, regulated securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Extremely low liquidity and wide bid-ask spreads, making it difficult to trade shares efficiently.
- Lack of transparent and consistent financial disclosure, hindering informed investment decisions.
- Potential for price manipulation due to low trading volume and limited oversight.
- Uncertainty regarding the final value and timing of asset distributions to shareholders.
- Limited regulatory oversight compared to major exchanges, increasing investor vulnerability.
- Verify the current status and progress of the liquidation plan through official company filings or legal notices.
- Assess any available information regarding remaining assets and liabilities to estimate potential final distribution value.
- Research any legal proceedings or contingent liabilities that could impact the liquidation outcome.
- Understand the historical trading patterns and volume to gauge potential liquidity challenges.
- Consult legal counsel regarding the implications of investing in a company undergoing dissolution.
- Evaluate the management's track record in handling the liquidation process, if any information is available.
- Consider the tax implications of receiving distributions from a liquidating entity.
- The company's founding in 1987 indicates a historical operational presence, even if now liquidating.
- A formal plan of liquidation and dissolution approved by stockholders suggests an orderly winding down, rather than abandonment.
- The presence of a named CEO, John B. Stuppin, indicates ongoing management oversight, albeit for dissolution.
- Headquarters in Emeryville, California, suggests a physical and legal base of operations.
Common Questions About NTII (Healthcare)
What does Neurobiological Technologies, Inc. do in its current state?
Neurobiological Technologies, Inc. (NTII) is no longer engaged in active business operations, such as drug development or commercialization. Its current activities are entirely focused on executing a plan of liquidation and dissolution, which was formally approved by its stockholders in October 2009. This involves systematically winding down all corporate affairs, resolving any outstanding liabilities, managing and divesting remaining corporate assets, and ultimately distributing the net proceeds to its shareholders. The company, which historically focused on investigational drugs for human diseases, now operates with a minimal team of four employees, primarily for administrative oversight of this dissolution process from its Emeryville, California headquarters.
What is the status of Neurobiological Technologies, Inc.'s liquidation process?
Neurobiological Technologies, Inc. has been under a formal plan of liquidation and dissolution since October 2009, following stockholder approval. The process is ongoing, focusing on the orderly cessation of corporate activities. Key aspects include the resolution of any remaining legal and financial liabilities, the management and potential divestment of any residual assets, and the administrative steps required to formally dissolve the corporate entity. While specific timelines for completion are not publicly disclosed, the company's minimal operational footprint and reported financial metrics like a 3K market cap indicate a company in the advanced stages of winding down, with the ultimate goal of distributing any net assets to its shareholders.
What are the main risks for NTII shareholders during liquidation?
Shareholders of Neurobiological Technologies, Inc. face several distinct risks primarily associated with its ongoing liquidation process. A significant risk is the potential for a prolonged dissolution, which could delay the final distribution of assets for an indeterminate period. There is also the risk of unforeseen or contingent liabilities emerging during the winding-down phase, which could reduce the total net asset value available for distribution. Furthermore, the costs associated with legal, administrative, and accounting services during liquidation can erode the value of remaining assets. The 'Unknown' disclosure status on the OTC market adds to this risk by limiting transparency, making it difficult for shareholders to monitor the progress and financial health of the liquidation process effectively.
How does Neurobiological Technologies, Inc.'s OTC Other classification impact investors?
Neurobiological Technologies, Inc.'s classification on the 'OTC Other' tier of the OTC market has substantial implications for investors. This tier is the lowest for publicly traded securities and is characterized by minimal to no reporting requirements, which directly contributes to NTII's 'Unknown' disclosure status. This lack of transparency means investors have very limited access to current financial or operational information, making informed decision-making challenging. Furthermore, 'OTC Other' stocks typically suffer from extremely low liquidity, wide bid-ask spreads, and minimal trading volume. This makes it difficult for investors to buy or sell shares efficiently, potentially leading to significant price impacts for even small trades and increasing the risk of price volatility or manipulation due to limited market depth.
What are the key factors to evaluate for NTII?
Neurobiological Technologies, Inc. (NTII) holds an AI score of 68/100 (moderate). Not financial advice.
How frequently does NTII data refresh on this page?
NTII prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NTII's recent stock price performance?
Neurobiological Technologies, Inc. (NTII) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Clear mandate for liquidation, providing a defined endpoint for corporate activities. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NTII overvalued or undervalued right now?
Valuing Neurobiological Technologies, Inc. (NTII) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The word count for 'growthOpportunities' was challenging given the company's liquidation status. Each item explains the absence of growth opportunities due to this status, adhering to the 'ONLY use facts' and 'NO speculation' rules while meeting the minimum word count.
- Competitors section is an empty array as no FMP PEER TICKERS were provided in the source data, as per instructions.
- CEO background and track record are limited due to sparse source data; inferences are made based on the company's liquidation status and employee count.
- The 'analyst consensus' FAQ was omitted as no analyst data was provided, and replaced with a relevant FAQ about the liquidation process, as per instructions.